Capricor Therapeutics, Inc.
CAPR
$6.54
-$0.0604-0.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -50.68% | -35.92% | -11.55% | 65.33% | 187.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.68% | -35.92% | -11.55% | 65.33% | 187.15% |
| Cost of Revenue | 54.51% | 44.87% | 37.10% | 38.53% | 54.44% |
| Gross Profit | -228.41% | -216.04% | -145.77% | -18.38% | 12.46% |
| SG&A Expenses | 43.42% | 26.12% | 16.08% | 15.19% | 15.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.87% | 40.16% | 31.63% | 32.20% | 43.13% |
| Operating Income | -144.67% | -118.97% | -76.78% | -17.13% | 1.55% |
| Income Before Tax | -150.39% | -126.48% | -81.57% | -16.64% | 4.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -150.39% | -126.48% | -81.57% | -16.64% | 4.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.39% | -126.48% | -81.57% | -16.64% | 4.38% |
| EBIT | -144.67% | -118.97% | -76.78% | -17.13% | 1.55% |
| EBITDA | -149.84% | -123.23% | -78.80% | -16.32% | 3.14% |
| EPS Basic | -76.39% | -62.09% | -37.47% | 7.86% | 20.23% |
| Normalized Basic EPS | -75.81% | -61.50% | -37.22% | 7.74% | 20.15% |
| EPS Diluted | -76.39% | -62.09% | -37.47% | 7.86% | 20.23% |
| Normalized Diluted EPS | -75.81% | -61.50% | -37.22% | 7.74% | 20.15% |
| Average Basic Shares Outstanding | 41.17% | 37.03% | 31.51% | 25.00% | 19.47% |
| Average Diluted Shares Outstanding | 41.17% | 37.03% | 31.51% | 25.00% | 19.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |